HK Stock Market Move | Concept stocks of brain-computer interface opened collectively. China has completed three cases of invasive brain-computer interface clinical trials.

date
09:29 18/12/2025
avatar
GMT Eight
Brain-machine concept stocks collectively opened higher. As of the time of writing, Brainhole Aurora (06681) rose 10.35% to HKD 6.29; Nanjing Panda Electronics Co. (00553) rose 1.63% to HKD 4.36.
Concept stocks related to brain-machine interfaces collectively opened higher. As of the time of publication, BrainCo (06681) rose by 10.35%, closing at 6.29 Hong Kong dollars; NANJING PANDA (00553) rose by 1.63%, closing at 4.36 Hong Kong dollars. On the news front, according to Securities Times, the research team of Zhao Zhengtuo and Li Xue from the Chinese Academy of Sciences Center for Excellence in Brain Science and Intelligent Technology has already collaborated with relevant hospitals and enterprises this year to complete three cases of invasive brain-machine interface clinical trials, achieving breakthroughs in the application of real-life scenarios. In the second clinical trial, the research team used a high-throughput wireless invasive brain-machine interface system to enable a high-level paralyzed patient to control an intelligent wheelchair and a robotic dog stably through brain signals, achieving independent movement and item access in real-life scenarios. China Securities Co., Ltd. believes that the technological progress in the middle and upper reaches of the brain-machine interface industry chain has continuously brought breakthroughs to the downstream application end. In recent years, milestone achievements have emerged in medical research in fields such as motor recovery, language communication, and hearing reconstruction both domestically and internationally. At the national and regional levels, various favorable policies have been introduced to accelerate the industry's development. Recently, the National Medical Insurance Administration issued a document separately listing the prices for new brain-machine interface technologies, paving the way for their entry into clinical applications. With technological innovation and policy dividends, domestic brain-machine interface companies are expected to gradually achieve commercial applications.